智通财经APP讯，同源康医药-B(02410)发布公告，有关与齐鲁达成许可及合作以及拟向认购方发行 6322.27万股H股相关事宜。认购事项须待认购协议项下的先决条件达成或获豁免后完成。倘认购事项的条件未能在经修订最后截止日期(即2026年9月20日)前达成或获豁免，认购协议将被终止。于本公告日期，认购协议项下的若干先决条件尚未达成或获豁免。
经审慎考虑当前市场状况及股份价格的近期变动，本公司与齐鲁已相互同意不再进一步延长经修订最后截止日期，而认购协议将因此根据其条款于经修订最后截止日期结束时(即2026年9月20日)失效。此后，除任何先前的违约行为外，任何一方概毋须承担认购协议项下的任何义务或责任。关于公告中所披露的许可及合作协议以及供应及商业化协议，齐鲁及本公司将继续遵守其各自于该等协议项下的义务。
董事会认为，认购协议失效将不会对本集团的业务营运及财务状况产生任何重大不利影响。双方仍有股份发行认购的合作意愿，具体细节仍在磋商中。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.